Masayuki Takeda Selected Research

Ipilimumab

4/2022	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
1/2022	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
8/2020	Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masayuki Takeda Research Topics

Disease

76	Neoplasms (Cancer) 04/2024 - 03/2003
59	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 03/2010
21	Overactive Urinary Bladder (Overactive Bladder) 03/2022 - 02/2005
17	Disease Progression 10/2022 - 11/2010
13	Lower Urinary Tract Symptoms 01/2020 - 07/2011
10	Neoplasm Metastasis (Metastasis) 12/2023 - 11/2005
10	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2017 - 09/2006
7	Nausea 05/2024 - 02/2016
7	Nocturia 11/2023 - 05/2013
7	Lung Neoplasms (Lung Cancer) 09/2021 - 05/2012
6	Colorectal Neoplasms (Colorectal Cancer) 09/2022 - 09/2011
6	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2006
6	Adenocarcinoma of Lung 01/2019 - 09/2012
5	Vomiting 05/2024 - 02/2016
5	Carcinoma (Carcinomatosis) 01/2022 - 07/2003
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 11/2005
4	Pain (Aches) 08/2023 - 07/2010
4	Diarrhea 01/2023 - 01/2015
4	Urinary Incontinence 01/2021 - 11/2016
4	Stomach Neoplasms (Stomach Cancer) 12/2016 - 01/2006
3	Exanthema (Rash) 01/2023 - 04/2015
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2018
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 07/2010
3	Infections 02/2017 - 09/2002
3	Inflammation (Inflammations) 01/2017 - 11/2005
2	Cancer Pain 08/2023 - 01/2023
2	Mesothelioma 01/2023 - 01/2015
2	Urge Urinary Incontinence (Urge Incontinence) 03/2022 - 05/2003
2	Urethral Stricture 02/2022 - 12/2021

Drug/Important Bio-Agent (IBA)

34	Tyrosine Kinase InhibitorsIBA 01/2023 - 12/2004
29	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2006
16	Gefitinib (Iressa)FDA Link 01/2023 - 12/2004
14	Biomarkers (Surrogate Marker)IBA 04/2024 - 12/2011
12	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2010
10	NivolumabIBA 04/2022 - 12/2016
9	osimertinibIBA 01/2023 - 01/2017
8	LigandsIBA 08/2023 - 01/2015
8	Alanine Transaminase (SGPT)IBA 01/2023 - 01/2015
8	AfatinibIBA 09/2019 - 04/2015
7	Immune Checkpoint InhibitorsIBA 04/2024 - 12/2016
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2015
7	Neuregulin-1 (Neuregulin 1)IBA 12/2019 - 09/2011
6	Pemetrexed (MTA)FDA Link 01/2023 - 11/2010
6	Tadalafil (Cialis)FDA Link 01/2020 - 09/2012
5	mirabegronIBA 03/2022 - 06/2014
5	Monoclonal AntibodiesIBA 06/2021 - 01/2011
5	nintedanibIBA 01/2021 - 01/2015
5	PlatinumIBA 01/2021 - 08/2012
5	Messenger RNA (mRNA)IBA 10/2019 - 04/2006
5	Cetuximab (Erbitux)FDA Link 09/2019 - 09/2011
5	Docetaxel (Taxotere)FDA Link 01/2019 - 08/2012
5	Carboplatin (JM8)FDA LinkGeneric 09/2013 - 07/2003
4	Morphine (MS Contin)FDA LinkGeneric 08/2023 - 12/2011
4	Opioid Analgesics (Opioids)IBA 08/2023 - 12/2011
4	Phosphotransferases (Kinase)IBA 10/2022 - 05/2012
4	Circulating Tumor DNAIBA 09/2021 - 01/2016
4	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2021 - 01/2018
4	SteroidsIBA 01/2021 - 03/2016
4	Proteins (Proteins, Gene)FDA Link 12/2019 - 01/2012
4	Connexin 43 (Connexin43)IBA 12/2019 - 01/2016
4	Trastuzumab (Herceptin)FDA Link 01/2019 - 03/2015
4	Anaplastic Lymphoma KinaseIBA 09/2018 - 05/2012
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 11/2005
4	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2014 - 01/2006
4	Paclitaxel (Taxol)FDA LinkGeneric 06/2013 - 07/2003
3	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 01/2021
3	palmidrolIBA 11/2023 - 10/2019
3	ParaffinIBA 09/2022 - 01/2019
3	Formaldehyde (Formol)FDA Link 09/2022 - 01/2019
3	RNA (Ribonucleic Acid)IBA 09/2022 - 04/2006
3	IpilimumabIBA 04/2022 - 08/2020
3	human ERBB2 proteinIBA 01/2022 - 03/2015
3	AcidsIBA 01/2022 - 10/2019
3	CytokinesIBA 01/2020 - 11/2005
3	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 08/2014
3	Muscarinic AntagonistsIBA 01/2019 - 02/2005
3	alectinibIBA 09/2018 - 11/2016
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 11/2016 - 05/2012
3	Bevacizumab (Avastin)FDA Link 04/2016 - 08/2012
3	Cholinergic Antagonists (Anticholinergics)IBA 10/2013 - 02/2005
3	Tamsulosin (Flomax)FDA LinkGeneric 10/2013 - 04/2011
2	Immune Checkpoint ProteinsIBA 04/2024 - 01/2018
2	B7-H1 AntigenIBA 04/2024 - 01/2022
2	Oxycodone (Oxycontin)FDA LinkGeneric 08/2023 - 01/2023
2	Carcinoembryonic AntigenIBA 01/2023 - 11/2016
2	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2023 - 05/2012
2	fosaprepitant FDA Link 10/2022 - 06/2022
2	selpercatinibIBA 10/2022 - 01/2021
2	PolymersIBA 02/2022 - 12/2021
2	Hormones (Hormone)IBA 01/2022 - 01/2018
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2020

Therapy/Procedure

49	Therapeutics 04/2024 - 11/2005
27	Drug Therapy (Chemotherapy) 05/2024 - 07/2003
7	Aftercare (After-Treatment) 01/2021 - 01/2015
7	Radiotherapy 01/2019 - 11/2005
6	Nephrectomy 12/2021 - 03/2003
5	Adjuvant Chemotherapy 04/2024 - 05/2012
4	Adrenalectomy 06/2022 - 05/2012
4	Immunotherapy 08/2020 - 11/2005
2	Operative Time 06/2022 - 12/2021